A prominent and successful example is the IMBrave150 trial, in which bevacizumab (anti-VEGF-A) with atezolizumab (anti-PD-L1) demonstrated superior overall survival (OS) over sorafenib, the standard of care first-line systemic therapy for metastatic hepatocellular carcinoma (HCC) [13]. The gene discussed is CD274; the disease is hepatocellular carcinoma.